J. Frank Nash

ORCID: 0000-0001-6133-9639
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurotransmitter Receptor Influence on Behavior
  • Skin Protection and Aging
  • Animal testing and alternatives
  • Dermatologic Treatments and Research
  • Neuroscience and Neuropharmacology Research
  • Contact Dermatitis and Allergies
  • Psychedelics and Drug Studies
  • Receptor Mechanisms and Signaling
  • Stress Responses and Cortisol
  • melanin and skin pigmentation
  • Forensic Toxicology and Drug Analysis
  • bioluminescence and chemiluminescence research
  • Cannabis and Cannabinoid Research
  • Bee Products Chemical Analysis
  • Tryptophan and brain disorders
  • Advancements in Transdermal Drug Delivery
  • Hair Growth and Disorders
  • Synthesis and Biological Evaluation
  • Indoor Air Quality and Microbial Exposure
  • Antioxidant Activity and Oxidative Stress
  • Diet and metabolism studies
  • Schizophrenia research and treatment
  • Neuroendocrine regulation and behavior
  • Chemical Safety and Risk Management
  • Olfactory and Sensory Function Studies

Procter & Gamble (United States)
2014-2025

Procter & Gamble (Netherlands)
2025

Procter & Gamble (United Kingdom)
2013

Boston Medical Center
2000

Newcastle upon Tyne Hospital
2000

Case Western Reserve University
1987-1995

University of Liverpool
1995

Royal Liverpool University Hospital
1995

Purdue University West Lafayette
1984-1994

Yonsei University
1992

Abstract: In vivo microdialysis was used to determine whether the 3,4‐methylenedioxymethamphetamine (MDMA)‐induced release of serotonin (5‐HT) in involves a carrier‐mediated process and investigate further state‐dependent interaction between 5‐HT dopamine. MDMA produced dose‐dependent increase extracellular concentration striatum prefrontal cortex that attenuated by treatment with fluoxetine but not tetrodotoxin. Suppression MDMA‐induced accompanied suppression Administration rats treated...

10.1046/j.1471-4159.1996.66010243.x article EN Journal of Neurochemistry 1996-01-01

The racemic mixture of 3,4-methylenedioxymethamphetamine (MDMA), which has been reported to produce selective destruction serotonergic neurons in the central nervous system, was studied determine its neuroendocrine and temperature effects mechanism action. MDMA elevated serum concentrations corticosterone doses ranging from 3 20 mg/kg administered i.p. Serum were 30 min after administration (10 i.p.) remained 4 hr later. prolactin (PRL) by 1 i.p., maximal 60 injection 10 declining rapidly...

10.1016/s0022-3565(25)24086-1 article EN Journal of Pharmacology and Experimental Therapeutics 1988-06-01

The effects of the amphetamine analog, 3,4-methylenedioxymethamphetamine (MDMA) were compared to d-amphetamine on in vivo release dopamine and gamma-aminobutyric acid (GABA) striatum substantia nigra. brain region-dependent role 5-HT2 receptors nigra regulating MDMA-induced GABA also was studied. Changes extracellular concentration dopamine, 5-HT measured simultaneously awake rat by microdialysis. increase striatal produced systemic administration MDMA attenuated infusion TTX into striatum....

10.1016/s0022-3565(25)09555-2 article EN Journal of Pharmacology and Experimental Therapeutics 1995-06-01

The effect of dopamine (DA) and serotonin (5-HT) uptake inhibitors on 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in DA efflux was studied using vivo microdialysis. MDMA infused directly into the anterolateral striatum via dialysis probe. local administration produced a dose- time-dependent extracellular concentration striatum. Peripheral blockers, mazindol (5 mg/kg, i.p.) or GBR 12909 (10 i.p.), slight but significant DA. Moreover, pretreatment with either 30 min before...

10.1016/s0022-3565(25)20405-0 article EN Journal of Pharmacology and Experimental Therapeutics 1991-11-01

• To examine further the serotoninergic system in obsessivecompulsive disorder (OCD), plasma concentrations of cortisol and prolactin behavioral responses after oral administration MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine), a serotonin agonist, placebo were studied 17 patients with OCD nine normal controls. The two groups did not differ significantly basal or levels. Nevertheless, both response to (20 mg) blunted compared those affect intensity symptoms. However, MK-212, as placebo,...

10.1001/archpsyc.1990.01810210041006 article EN Archives of General Psychiatry 1990-09-01

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXT1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: A Potent Serotonin 5-HT2A/2C AgonistDavid E. Nichols, Stewart Frescas, Danuta Marona-Lewicka, Xuemei Huang, Bryan L. Roth, Gary A. Gudelsky, and J. Frank NashCite this: Med. Chem. 1994, 37, 25, 4346–4351Publication Date (Print):December 1, 1994Publication History Published online1 May 2002Published inissue 1 December...

10.1021/jm00051a011 article EN Journal of Medicinal Chemistry 1994-12-01
Coming Soon ...